Explorez tous les épisodes du podcast Eagle's Eye View: Your Weekly CV Update From ACC.org
| Titre | Date | Durée | |
|---|---|---|---|
| Risk Stratification in Nonischemic Dilated Cardiomyopathy, 2024 Guideline for Perioperative CV Management for Noncardiac Surgery, Lipoprotein(a) and Cardiovascular Disease | 25 Sep 2024 | 00:08:53 | |
In this week's View, Dr. Eagle looks at risk stratification in nonischemic dilated cardiomyopathy using CMR imaging. He then discusses the recent update of the Guideline for Perioperative CV Management for Noncardiac Surgery. Finally, Dr. Eagle talks about a review article on lipoprotein(a) and CVD. | |||
| Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome | 18 Sep 2024 | 00:10:36 | |
In this week's View, Dr. Eagle looks at predicting long-term outcomes in patients with recurrent pericarditis. He then explores how the polygenic risk score may add to the clinical risk estimate for predicting cardiovascular disease in populations. Finally, Dr. Eagle discusses the management of aortic disease in children with FBN1-related Marfan syndrome. | |||
| Diuretics and HF, Implantable Cardioverter-Defibrillators and the Tricuspid Valve and Right Ventricle, Neurohormonal Blockade and HF | 24 Jul 2024 | 00:08:47 | |
In this week's View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF). He then explores a randomized trial that investigates the effects of implantable cardioverter-defibrillator (ICD) leads on the tricuspid valve and right ventricle. Finally, Dr. Eagle discusses the effects of rapid up-titration of neurohormonal blockade in patients with acute decompensated HF. | |||
| Racial Differences in Diabetic Cardiomyopathy, Genetics of HCM, Semaglutide vs. Tirzepatide for Weight Loss | 17 Jul 2024 | 00:08:59 | |
In this week's View, Dr. Eagle looks at the ARISE-HF trial that examined racial differences in diabetic cardiomyopathy. He then explores established and emerging implications of treatment of genetic hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the use of GLP-1 agonists, including semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity.
| |||
| Iron Repletion and Heart Failure, Ventricular Septal Defect and Acute Myocardial Infarction, Hemodynamic Assessment for HF | 10 Jul 2024 | 00:09:09 | |
In this week's View, Dr. Eagle discusses a state-of-the-art review on iron repletion for patients with heart failure and iron deficiency. He then explores the diagnosis and management of ventricular septal defect complicating acute myocardial infarction. Finally, Dr. Eagle discusses practical guidance for hemodynamic assessment by right heart catheterization in management of heart failure. | |||
| Early Rhythm Control, Low-Dose Aspirin and Prevention, Autoimmune Diseases and Atherosclerosis | 02 Jul 2024 | 00:08:37 | |
In this week's View, Dr. Eagle looks at the clinical impact of early rhythm control and healthy lifestyles in patients with atrial fibrillation, then explores the use of low-dose aspirin in the prevention of atherosclerotic cardiovascular disease. Finally, Dr. Eagle discusses the association of autoimmune diseases with coronary atherosclerosis and ischemic events. | |||
| Eight Practice-Changing Trials Featured at ESC Congress 2024 | 12 Sep 2024 | 00:11:02 | |
In this special edition of Eagle's Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF. | |||
| Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients | 11 Sep 2024 | 00:08:25 | |
In this week's View, Dr. Eagle looks at temporary mechanical circulatory support in infarct-related cardiogenic shock. He then explores the anticoagulation benefit in device-detected atrial fibrillation with or without vascular disease as reported in a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Finally, Dr. Eagle discusses a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials that documented the effectiveness of semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction. | |||
| SGLT2 Inhibitors vs. GLP-1 RAs in Diabetes, MRI Lesions After TAVR, Perioperative Management and Anticoagulants | 04 Sep 2024 | 00:09:50 | |
In this week's View, Dr. Eagle looks at the kidney and cardiovascular effectiveness of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes. He then explores the prognostic ability of diffusion-weighted brain MRI lesions after TAVR. Finally, Dr. Eagle discusses perioperative management of patients taking direct oral anticoagulants, particularly those being considered for noncardiac surgery. | |||
| Social Determinants of Health in Cardiology, Aortopathy in Children, Cardiac CT Following Left Atrial Appendage Occlusion | 28 Aug 2024 | 00:11:00 | |
In this week's View, Dr. Eagle looks at the 2024 ACC/AHA key data elements and definitions for social determinants of health in cardiology. He then explores key points of management of aortopathy in children. Finally, Dr. Eagle discusses the recent position statement on the use of cardiac CT following left atrial appendage occlusion. | |||
| Genetics and Risk in Aortic Disease, Plant vs. Animal Fat in Cardiovascular Outcomes, Management of Cardiac Sarcoidosis | 21 Aug 2024 | 00:10:38 | |
In this week's View, Dr. Eagle looks at the potential role of genetics in predicting risk in people with aortic disease. He then compares plant and animal fat intake in overall cardiovascular disease outcomes. Finally, Dr. Eagle discusses a clinical consensus statement on the management of cardiac sarcoidosis from the European community. | |||
| Update to ACC/AHA Heart Failure Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and Chronic Kidney Disease | 14 Aug 2024 | 00:08:27 | |
In this week's View, Dr. Eagle looks at the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure (HF). He then explores the eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed HF. Finally, Dr. Eagle discusses a systematic review of clinical trials investigating the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) for advanced chronic kidney disease (CKD). | |||
| Pulmonary Hypertension and HF, Obesity in Adolescents, Noncardiac Surgery After TAVR | 07 Aug 2024 | 00:07:26 | |
In this week's View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health. Finally, Dr. Eagle discusses a national analysis of the timing of noncardiac surgery following transcatheter aortic valve replacement (TAVR): is there an optimal time for surgery after TAVR? | |||
| Fenestrated-Branched Endovascular Aortic Repair, Mortality and PCI, Lp(a) and Calcific Aortic Stenosis Progression | 31 Jul 2024 | 00:09:41 | |
In this week's View, Dr. Eagle looks at a prospective multicenter cohort study that examined early and late aortic-related mortality and rupture after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms. He then explores periprocedural mortality in patients having PCI and a rise in biomarkers. Finally, Dr. Eagle discusses a systemic review and meta-analysis of lipoprotein(a) and calcific aortic valve stenosis progression. | |||
| Top Six Trials From AHA 2024: BROAD, SUMMIT, OPTION, CLEAR SYNERGY (Spironolactone and Colchicine), My Heart Your Heart | 21 Nov 2024 | 00:12:55 | |
In this special edition of Eagle's Eye View, Dr. Eagle looks at the most important trials presented at the recent AHA scientific sessions: 1) BROAD, exploring more intensive blood pressure control; 2) SUMMIT, evaluating tirzepatide use in obesity-related HFpEF in people with diabetes; 3) OPTION, comparing left atrial appendage closure to oral anticoagulation therapy for stroke protection in post-ablation patients with atrial fibrillation; 4) CLEAR SYNERGY, dual trials on the use of spironolactone vs. placebo and colchicine vs. placebo in patients with myocardial infarction, and 5) Project My Heart Your Heart, developing a protocol of the use of refurbished pacemakers. | |||
| Exercise Training in HCM; Management of Kawasaki Disease; Race, Social Determinants of Health, Polygenic Risk for CHD | 20 Nov 2024 | 00:08:38 | |
In this week's View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM). He then reviews the diagnosis and management of Kawasaki Disease. Finally, Dr. Eagle discusses the association of self-reported race, social determinants of health (SDoH), and polygenic risk for coronary heart disease (CHD). | |||
| Transseptal Mitral Valve-in-Valve Procedure, Complete vs. Culprit-Only Revascularization in Older Patients, Hypertensive Pregnancy and MI Risk | 13 Nov 2024 | 00:08:07 | |
In this week's View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs. culprit-only revascularization in older patients with myocardial infarction (MI) with or without ST-segment elevation. Finally, Dr. Eagle discusses hypertensive disorders of pregnancy and whether they increase the risk for MI. | |||
| TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure | 06 Nov 2024 | 00:07:06 | |
In this week's View, Dr. Eagle looks at the outcomes of balloon-expandable transcatheter aortic valve replacement (TAVR) in younger patients. He then explores the comparative effectiveness and safety of atorvastatin versus rosuvastatin. Finally, Dr. Eagle discusses the results of the RESET-BP randomized trial that studied the effects of sedentary behavior's reduction of blood pressure in desk workers. | |||
| Top Four Trials from TCT 2024: EARLY TAVR, TRISCEND II for Tricuspid Regurgitation, ECLIPSE on orbital atherectomy, and CLEAR SYNERGY (OASIS 9) & colchicine treatment | 05 Nov 2024 | 00:09:55 | |
In this special edition of Eagle's Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; 2) TRISCEND II looking at the Evoque transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation; 3) ECLIPSE evaluating orbital atherectomy prior to drug-eluting stent implant compared to conventional PCI; and 4) CLEAR SYNERGY (OASIS 9) assessing the effects of colchicine after PCI for a STEMI or large NSTEMI. | |||
| Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses | 30 Oct 2024 | 00:08:43 | |
In this week's View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension. | |||
| Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI | 23 Oct 2024 | 00:08:51 | |
In this week's View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis. | |||
| Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS | 16 Oct 2024 | 00:09:51 | |
In this week's View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS). | |||
| CV Events After COVID Vaccine, Septal Reduction in Obstructive HCM, Acute Pulmonary Embolism Guideline Comparison | 09 Oct 2024 | 00:10:33 | |
In this week's View, Dr. Eagle looks at cardiovascular events following COVID vaccination in adults. He then explores long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses clinical practice guideline recommendations for acute pulmonary embolism. | |||
| Hospital Survival After AAA Repair, Myocardial Fibrosis and Aortic Stenosis, MRA Use in HF | 02 Oct 2024 | 00:07:50 | |
In this week's View, Dr. Eagle looks at sex-specific differences in alive hospital discharge following abdominal aortic aneurysm (AAA) repair. He then explores how diffuse interstitial fibrosis of the myocardium predicts outcomes in moderate and asymptomatic severe aortic stenosis. Finally, Dr. Eagle discusses the value of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF). | |||
| Compression Socks & Vasovagal Syncope; Management of Pericarditis; Early Cardiac Rehab for ADHF. | 14 Aug 2025 | 00:08:08 | |
In this week's View, Dr. Eagle looks at whether compression stockings reduce vasovagal syncope recurrence. He then discusses new concise clinical guidance that addresses the evaluation and management of pericarditis. Finally, Dr. Eagle explores early, safe cardiac rehabilitation for critically ill patients hospitalized with acute decompensated heart failure (ADHF).
| |||
| BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement | 30 Jul 2025 | 00:07:02 | |
In this week's View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair. | |||
| ORBITA-2 & PCI; Blood Pressure Control & Increasing Medication Prescriptions; Rapid Initiation & Titration in GRMT for Patients with HFrEF | 14 May 2025 | 00:08:19 | |
In this week's View, Dr. Eagle looks at the results of the ORBITA-2 Trial and its use in stress echocardiography before PCI. He then discusses the proportion of patients achieving blood pressure (BP) control plateaus despite increasing medication prescriptions. Finally, Dr. Eagle explores the use of rapid initiation and titration in guideline-recommended medical therapy (GRMT) in patients with heart failure with reduced ejection fraction (HFrEF).
| |||
| Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib | 30 Apr 2025 | 00:08:34 | |
In this week's View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation (AFib). | |||
| Weight Management in Pregnancy and CVD Risk; Impact of Statins Plus Ezetimibe Post-MI; PARTNER-3 Study 5-year Results | 23 Apr 2025 | 00:06:52 | |
In this week's View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the echocardiographic outcomes at five years. | |||
| Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs) | 16 Apr 2025 | 00:07:26 | |
In this week's View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores OCEANIC-AF, a study that analyzes the differences in outcomes in patients with and without prior use of oral anti-coagulants (OACs). | |||
| Key Takeaways from ACC.25 Major Trials and Presentations | 02 Apr 2025 | 00:09:25 | |
In this week's View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including:
| |||
| Cardiogenic Shock Guidance; Mortality after Mitral Repair & TAVR; Direct-to-Physician Marketing Affects GDMT | 26 Mar 2025 | 00:07:55 | |
In this week's View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients. | |||
| Smoking & CVD Risk; Sleep, Diabetes, & Women with Gestational Diabetes; Post-TAVR Imaging | 19 Mar 2025 | 00:07:01 | |
In this week's View, Dr. Eagle examines the dose-response relationship between smoking and subclinical cardiovascular disease markers. He then discusses how the effect of poor sleep increases diabetes risk in women who have had gestational diabetes. Finally, Dr. Eagle offers a look into imaging post-transcatheter aortic valve replacement (TAVR) in patients who may have valve failure. | |||
| Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF | 12 Mar 2025 | 00:06:56 | |
In this week's View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients. | |||
| Identifying Myocardial Infarction after PCI; Myocardial Fibrosis & Severe Aortic Valve Stenosis; Anticoagulation & Cancer Diagnoses | 05 Mar 2025 | 00:07:56 | |
In this week's View, Dr. Eagle looks at the optimal threshold for identifying a myocardial infarction (MI) after PCI. He then discusses myocardial fibrosis and its prognostic features in patients undergoing treatment for severe aortic valve stenosis. Finally, Dr. Eagle explores the relationship between bleeding after initiation of anticoagulation and cancer diagnoses.
| |||
| SGLT2 Inhibitors & Aortic Valve Stenosis; Early vs. Later Ablation for Afib; Sports Participation by Athletes with Cardiac Abnormalities | 26 Feb 2025 | 00:08:47 | |
In this week's View, Dr. Eagle looks at the potential exposure-dependent protective effect of SGLT2 inhibitors on aortic valve stenosis progression. He then discusses the potential value of earlier ablation for atrial fibrillation versus later ablation. Finally, Dr. Eagle explores new guidance for sports participation by athletes with cardiac abnormalities. | |||
| The PREVENT Model & Risk Prediction; Carbohydrate Quality & Improved LV Structure; Radial Access for PCI & Lower Complication Rates | 23 Jul 2025 | 00:07:18 | |
In this week's View, Dr. Eagle looks at the PREVENT model and its ability to predict ten-year atherosclerotic cardiovascular disease risk in diverse populations. He then discusses higher carbohydrate quality and fiber-rich foods and their links to better cardiac structure and function. Finally, Dr. Eagle explores increased use of radial access for percutaneous coronary intervention to achieve lower complication rates. | |||
| Arrhythmia Recurrence & Rhythm Control after Catheter Ablation for AFib; Transthyretin Amyloid Cardiomyopathy & Tafamidis; Sodium Restriction & BP | 19 Feb 2025 | 00:06:17 | |
In this week's View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis. Finally, Dr. Eagle explores a population study on the effect of sodium restriction in food and its potential effects on blood pressure. | |||
| Blood Pressure & Postpartum; Beta Blockers & Takotsubo Syndrome; Secondary Prevention Worldwide | 12 Feb 2025 | 00:07:51 | |
In this week's View, Dr. Eagle looks at tighter blood pressure control in patients who are postpartum. He then discusses beta blocker therapy in patients with Takotsubo syndrome. Finally, Dr. Eagle explores secondary prevention and medications around the world. | |||
| Cardiac Rehab & Heart Failure, CV Care & Cancer Survivors, Bioprosthetic AVR vs Mechanical AVR in Younger Patients | 05 Feb 2025 | 00:06:10 | |
In this week's View, Dr. Eagle looks at cardiac rehabilitation for people with heart failure. He then discusses managing cardiovascular (CV) disease in cancer survivors who have completed cancer therapy. Finally, Dr. Eagle explores bioprosthetic aortic valve replacement (AVR) versus mechanical AVR in younger patients. | |||
| Cost-effectiveness of Polypills, Obesity and FH, Adverse Pregnancy Outcomes and Long-term HF Risk | 29 Jan 2025 | 00:08:03 | |
In this week's View, Dr. Eagle examines the cost-effectiveness of polypills. He then discusses overweight and obesity in patients with familial hyperlipidemia. Finally, Dr. Eagle explores how adverse pregnancy outcomes are associated with long-term risk of heart failure. | |||
| Left Atrial Appendage Occlusion & Stroke, Hypertrophic Cardiomyopathy in Children, Anticoagulation & COVID-19 | 22 Jan 2025 | 00:06:43 | |
| Top Trials, Journal Scans, and Takeaways of 2024 | 23 Dec 2024 | 00:05:37 | |
In this week's special edition of Eagle's Eye View, Dr. Eagle looks at the top trials, journal scans, and clinical developments in cardiology that have changed your practice and will continue to change clinical care in the future. | |||
| What Cardiologists Should Know About Congenital Heart Disease, Cardiac Arrest and Death in Athletes, Arrhythmia After Stroke | 18 Dec 2024 | 00:10:33 | |
In this week's View, Dr. Eagle looks at what adult cardiologists should know about congenital heart disease patients. He then discusses sudden cardiac arrest and death in competitive and recreational athletes. Finally, Dr. Eagle explores practical approaches for arrhythmia monitoring after stroke. | |||
| Management of Myocarditis; Sex Differences in PCI vs. CABG; RVOT Dysfunction in Repaired TOF | 11 Dec 2024 | 00:09:35 | |
In this week's View, Dr. Eagle looks at the 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. He then discusses sex differences in patients undergoing FFR-guided PCI or CABG in the FAME 3 Trial. Finally, Dr. Eagle explores long-term management of right ventricular outflow tract (RVOT) dysfunction in repaired tetralogy of Fallot (TOF).
| |||
| Compression Tights in Patients With POTS, Platelet Function and Genetic Testing in PCI, Aspirin in Stent Patients Undergoing Noncardiac Surgery | 04 Dec 2024 | 00:09:19 | |
In this week's View, Dr. Eagle looks at the use of waist-high compression tights in patients with postural orthostatic tachycardia syndrome (POTS). He then discusses a consensus statement on platelet function and genetic testing in percutaneous coronary intervention (PCI). Finally, Dr. Eagle explores aspirin monotherapy versus no antiplatelet therapy in stable patients with coronary stents undergoing low-to-intermediate-risk noncardiac surgery. | |||
| Prevalence of U.S. Overweight and Obesity, Consensus on CPR, Bleeding Risk Using NSAIDs With Anticoagulants | 27 Nov 2024 | 00:08:05 | |
In this week's View, Dr. Eagle looks at the prevalence of overweight and obesity among children, adolescents, and adults in the U.S., with forecasts up to 2050. He then discusses consensus recommendations on cardiopulmonary resuscitation (CPR). Finally, Dr. Eagle explores bleeding risk using nonsteroidal anti-inflammatory drugs (NSAIDs) with anticoagulants after venous thromboembolism. | |||
| AV after TTVR; Deep Learning in Automating Cardiac IMG; Survival Benefits Post-2018 Heart Transplantation Policy Change | 16 Jul 2025 | 00:08:08 | |
In this week's View, Dr. Eagle looks at predictors of high-grade atrioventricular block (AV) after transcatheter tricuspid valve replacement (TTVR). He then discusses the challenges and benefits of deep learning in automating cardiac imaging (IMG). Finally, Dr. Eagle explores higher survival benefits after the 2018 U.S. Heart Transplantation Allocation policy change. | |||
| Ischemic Preconditioning & Noncardiac Surgery; The Microaxial Flow Pump in STEMI-CS; DOACs After Strokes | 09 Jul 2025 | 00:07:03 | |
In this week's View, Dr. Eagle looks at whether ischemic preconditioning provides benefit in noncardiac surgery. He then discusses the benefits of the microaxial flow pump in STEMI-cardiogenic shock (CS) patients undergoing hemodynamic monitoring. Finally, Dr. Eagle explores starting direct oral anticoagulants (DOACs) early after stroke, and whether it lowers the risk of future strokes and hemorrhage. | |||
| Frailty Status and Mortality Risk in PCI; Delays in Treatment in STEMI; Arterial Events with Genetic-based Vascular Disease | 25 Jun 2025 | 00:07:28 | |
In this week's View, Dr. Eagle looks at frailty status and increased risk of mortality in patients who undergo percutaneous coronary intervention (PCI). He then discusses the timely treatment and delays in treatment of ST-segment elevation myocardial infarction (STEMI) that are associated with worse outcomes. Finally, Dr. Eagle explores new insights on arterial events associated with heritable thoracic aortic disease and the relative risk in patients with pathogenic variants, as well as the prevalence, characteristics, and clinical outcomes of arterial aneurysms in Loeys-Dietz Syndrome. | |||